Where Will Pandora Go Post-Earnings?

With shares of Pandora (NYSE:P) trading around $29, is P an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Pandora is an Internet radio company that operates in the United States with over 125 million registered users. Pandora's Music Genome Project and its playlist-generating algorithms predict listener music preferences, play music content suited to the tastes of each individual listener, and introduce listeners to music they will love. The main sources of revenue for the company are advertising as well as subscriptions. As the Internet music boom continues, Pandora is well-positioned to capitalize on potential subscriptions and advertising marketing share.

Pandora reported third-quarter earnings after the closing bell on Thursday that came in line with analyst estimates. Pandora reported a loss of 1 cent per share on sales of $180.4 million compared to last year's gain of 1 cent per share on sales of $120 million. Earnings came in at 6 cents per share; analysts had expected the company to earn 6 cents per share and report sales of $177 million, according to MarketWatch. Pandora is being closely watched as Apple (NASDAQ:AAPL) released a competing online radio service, iTunes Radio, this fall.

T = Technicals on the Stock Chart Are Strong

Pandora stock has been surging higher over the last several quarters. The stock is currently trading near highs for the year and looks poised to continue. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Pandora is trading above its rising key averages, which signal neutral to bullish price action in the near-term.

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of Pandora options may help determine if investors are bullish, neutral, or bearish.

	Implied Volatility (IV)	30-Day IV Percentile	90-Day IV Percentile
Pandora Options	52.05%	0%	0%

What does this mean? This means that investors or traders are buying a very small amount of call and put options contracts as compared to the last 30 and 90 trading days.

	Put IV Skew	Call IV Skew
December Options	Hot Value Stocks To Buy For 2015 Flat	Average
January Options	Flat	Average

As of today, there is an average demand from call buyers or sellers and low demand by put buyers or high demand by put sellers, all neutral to bullish over the next two months. To summarize, investors are buying a very small amount of call and put option contracts and are leaning neutral to bullish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on Pandora’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for Pandora look like and more importantly, how did the markets like these numbers?

	2013 Q3	2013 Q2	2013 Q1	2012 Q4
Earnings Growth (Y-O-Y)	20.00%	1200.00%	-11.11%	-69.72%
Revenue Growth (Y-O-Y)	50.28%	51.18%	59.07%	53.81%
Earnings Reaction	-1.52%*	-12.89%	-4.25%	17.56%

Pandora has seen mixed earnings and increasing revenue figures over the last four quarters. From these numbers, the markets have been pleased with Pandora’s recent earnings announcements.

* As of this writing

P = Excellent Relative Performance Versus Peers and Sector

How has Pandora stock done relative to its peers, Sirius XM Radio (NASDAQ:SIRI), CBS (NYSE:CBS), Cumulus Media (NASDAQ:CMLS), and sector?

	Pandora	Sirius XM Radio	CBS	Cumulus Media	Sector
Year-to-Date Return	213.10%	27.16%	54.22%	150.90%	112.34%

Pandora has been a relative performance leader, year-to-date.

Conclusion

Pandora is an Internet radio company that attempts to match listeners with their preferences in order to discover music they love. The company reported third-quarter earnings after the closing bell on Thursday that came in line with analyst estimates. The stock has been rising higher in recent quarters and is now trading near highs for the year. Over the last four quarters, earnings have been mixed while revenues have been rising, however, investors have expected more from the company. Relative to its peers and sector, Pandora has been a year-to-date performance leader. Look for Pandora to continue to OUTPERFORM.

Thirsty? There's a global wine shortage

Wine producers, like these harvesters in Spain, are falling behind the worldwide rise in demand.

NEW YORK (CNNMoney) There's just not enough wine in the world, says Morgan Stanley, and the problem is only going to get worse.

The industry is experiencing an "undersupply of nearly 300 million cases" a year, according to a report from Morgan Stanley Research.

Australia-based analysts Tom Kierath and Crystal Wang say the shortage comes despite the fact that there are one million wine producers globally, making 2.8 million cases each year. About half of that comes from Europe.

But that's not enough to keep with worldwide demand

Global production fell by more than 5% last year - to its lowest level since the 1960s - primarily do to bad weather in France and Argentina.

Top Small Cap Stocks To Own Right Now

Production in Europe alone dropped 10% in 2012, the report said. That same year, worldwide consumption rose by 1%.

The French consume the most wine, followed by Americans, and then the Chinese.

Wine has become particularly popular in China, as the economy booms and the standard of living there rises. China is also producing more wine of its own, said the report.

America consumes 12% of the world's wine but produces just 8%. And the U.S. is only getting thirstier ; consumption rose 2% last year.

The U.S. wine making industry is also growing. The number of American wineries has "expanded dramatically" in the last 15 years, according to the report. But most of them are "boutique" operators rather than major producers, so they're not driving any real growth in supply.

And there is little reason to believe that global wine production will pick up any time soon.

Morgan Stanley said that output from newer producers like the U.S., Argentina, Chile, Australia, New Zealand and South Africa has already peaked.

Hot European Stocks To Buy For 2015

AMSTERDAM (AP) -- A top lawyer at the European Court of Justice said Tuesday that�Google (NASDAQ: GOOG  ) and other search engines should not have to remove web pages containing personal information from their search indexes.

In a blow for the "right to be forgotten" privacy principle in Europe, the court's independent Advocate General, Niilo Jaaskinen, said in a formal opinion that websites, not�Google, should bear responsibility for information they publish.

Jaaskinen said�Google's�search function "does not imply any control over the content included on third party web pages." His opinion is not binding, but judges will typically follow much of its reasoning when they issue their decision later this year.

Google's�information indexing system "does not even enable the Internet search engine provider to distinguish between personal data...and other data," Jaaskinen said.

The Luxembourg-based ECJ was asked to weigh in on the issue after a case in Spain, where the national data protection agency received complaints from individuals who said personal information from years earlier could be found on a simple Internet search.

Hot European Stocks To Buy For 2015: Aercap Holdings N.V. (AER)

AerCap Holdings N.V., through its subsidiaries, operates as an integrated aviation company worldwide. It engages in leasing and trading aircraft and engines; and selling parts. The company also provides aircraft management services, as well as aircraft and limited engine MRO services, and aircraft disassembly services through its repair stations. In addition, it offers aircraft services, including remarketing aircraft; collecting rental and maintenance payments, monitoring aircraft maintenance, monitoring and enforcing contract compliance, and accepting delivery and redelivery of aircraft; conducting ongoing lessee financial performance reviews; inspecting the leased aircraft; coordinating technical modifications to aircraft to meet new lessee requirements; conducting restructurings negotiations in connection with lease defaults; repossessing aircraft; arranging and monitoring insurance coverage; registering and de-registering aircraft; arranging for aircraft and aircraft engine valuations; and providing market research. The company?s management services include leasing and remarketing, cash management and treasury, technical advisory, and accounting and administrative services. As of March 31, 2011, it owned 272 aircraft and 95 engines, which it leased under operating leases to 118 lessees in 53 countries. The company was founded in 1995 and is headquartered in Schiphol, the Netherlands.

Advisors' Opinion:

• [By Roberto Pedone]

  AerCap (AER) provides aircraft leasing and aviation finance services. This stock closed up 3.3% at $18 in Wednesday's trading session.

  Wednesday's Volume: 740,000
  
  Three-Month Average Volume: 318,589
  
  Volume % Change: 85%

  From a technical perspective, AER jumped higher here right above its 50-day moving average of $17.27 with above-average volume. This stock has been uptrending strong for the last five months, with shares moving higher from its low of $14.84 to its recent high of $18.16. During that uptrend, shares of AER have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of AER within range of triggering a near-term breakout trade. That trade will hit if AER manages to take out its 52-week high at $18.16 with high volume.

  Traders should now look for long-biased trades in AER as long as it's trending above its 50-day at $17.27 or above more near-term support at $17.17 and then once it sustains a move or close above its 52-week high at $18.16 with volume that's near or above 318,589 shares. If that breakout hits soon, then AER will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $20 to $23.

• [By Paul Ausick]

  More than two years ago, American International Group Inc. (NYSE: AIG) filed with the U.S. Securities and Exchange Commission for an initial public offering (IPO) in its aircraft leasing group, International Lease Finance Corp. (ILFC). That filing came to nothing, and AIG found little interest from buyers for ILFC, until Monday morning when it announced that AerCap Holdings N.V. (NYSE: AER) will buy the leasing operation for $3 billion in cash and 97.56 million shares of new AerCap stock. The total value of the deal is approximately $5.4 billion.

• [By Ben Levisohn]

  Finally. Finally American International Group (AIG) has disposed of its ILFC unit by selling it to AerCap Holdings (AER).

  Bloomberg News

  The Wall Street Journal has the details on the deal:

• [By John Udovich]

  Yesterday around midday,�Netherlands based aviation leasing stock�AerCap Holdings N.V. (NYSE: AER) began surging on rumors and closed up 11.6%, meaning its probably time to take a closer look at those rumors along with aviation leasing peers like small caps or mid caps�Aircastle Limited (NYSE: AYR), Air Lease Corp (NYSE: AL), Fly Leasing Ltd (NYSE: FLY) and AeroCentury Corp (NYSEMKT: ACY).

Hot European Stocks To Buy For 2015: Telefonica SA(TEF)

Telefonica, S.A. provides fixed and mobile telephony services primarily in Spain, rest of Europe, and Latin America. Its fixed telecommunication services include PSTN lines; ISDN accesses; public telephone; local, domestic, and international long distance and fixed-to-mobile communications; corporate communications; video telephony; supplementary and business-oriented value-added services; network services; leasing and sale of handset equipment; and telephony information services. The company?s Internet and broadband multimedia services comprise Internet service provider service; portal and network services; retail and wholesale broadband access; narrowband switched access to Internet; naked ADSL, a broadband connection; residential-oriented value-added services; companies-oriented value-added services; television services, such as IPTV, cable television, and satellite television; and Fiber to the Home, a service for high speed Internet access and digital video recording. Its data and business-solutions services principally include leased lines; virtual private network services; fiber optics services; the provision of hosting and application; outsourcing and consultancy services; desktop services; and system integration and professional services. The company?s wholesale services for telecommunication operators primarily comprise domestic interconnection services; international wholesale services; leased lines for other operators? network deployment; local loop leasing under the unbundled local loop regulation framework; and bit stream services. It also offers various mobile and related services and products that include mobile voice services, value added services, mobile data and Internet services, wholesale services, corporate services, roaming, fixed wireless, and trunking and paging services. The company has a strategic alliance with China Unicom (Hong Kong) Limited. Telefonica, S.A. was founded in 1924 and is headquartered in Madrid, Spai n.

Advisors' Opinion:

• [By Dan Caplinger]

  You can see the same trends among many individual European stocks. Telecom giant Telefonica (NYSE: TEF  ) has big exposure to Latin America, but investors focus on its home country of Spain in limiting its gains. The same trend has affected French oil giant Total (NYSE: TOT  ) , which shares the same exposure to energy projects around the world yet has been tarnished by its proximity to the crisis-ridden continent. By focusing on value rather than perception, you can get some great values when others are being irrational.

Top 5 Blue Chip Stocks To Buy Right Now: BP p.l.c.(BP)

BP p.l.c. provides fuel for transportation, energy for heat and light, retail services, and petrochemicals products. Its Exploration and Production segment engages in the oil and natural gas exploration, field development, and production; midstream transportation, and storage and processing; and marketing and trading of natural gas, including liquefied natural gas (LNG), and power and natural gas liquids (NGL). This segment has exploration and production activities in Angola, Azerbaijan, Canada, Egypt, Norway, Russia, Trinidad and Tobago, the United Kingdom, and the United States, as well as in Asia, Australasia, South America, North Africa, and the Middle East. This segment also owns and manages crude oil and natural gas pipelines; processing facilities and export terminals; and LNG processing and transportation, as well as NGL extraction facilities. BP p.l.c. has interests in the Trans-Alaska pipeline system, the Forties pipeline system, the Central Area transmission sys tem pipeline, the South Caucasus Pipeline, and Baku-Tbilisi-Ceyhan pipeline, as well as in LNG plants located in Trinidad, Indonesia, and Australia. The company?s Refining and Marketing segment involves in the supply and trading, refining, manufacturing, marketing, and transportation of crude oil, petroleum, and petrochemicals products and related services to wholesale and retail customers primarily under the BP, Castrol, ARCO, and Aral brands. Its Other Businesses and Corporate segment produces and markets rolled aluminum products, as well as generates energy through wind, solar, biofuels, hydrogen, and carbon capture and storage sources; and engages in shipping activities. The company was founded in 1889 and is headquartered in London, the United Kingdom.

Advisors' Opinion:

• [By Roland Head]

  LONDON -- BP� (LSE: BP  ) (NYSE: BP  ) issued decent first-quarter results earlier this week, but its shareholders are probably more interested in whether the eventual outcome of the firm's Clean Water Act trial in New Orleans could threaten its attractive 5.1% dividend yield.

• [By Tony Reading]

  In this series I'm subjecting companies to scrutiny under five headings: prospects, performance, management, safety and valuation. How does�BP� (LSE: BP  ) (NYSE: BP  ) measure up?

Hot European Stocks To Buy For 2015: TotalFinaElf S.A.(TOT)

TOTAL S.A., together with its subsidiaries, operates as an integrated oil and gas company worldwide. The company operates through three segments: Upstream, Downstream, and Chemicals. The Upstream segment engages in the exploration, development, and production of oil and natural gas. It also involves in the transportation, trade, and marketing of natural gas and liquefied natural gas (LNG), as well as in LNG re-gasification and natural gas storage operations. In addition, this segment engages in the shipping and trade of liquefied petroleum gas (LPG); power generation from gas-fired power plants, nuclear, or renewable energies; production, trade, and marketing of coal, as well as in solar power systems and technology operations. As of December 31, 2010, it had combined proved reserves of 10,695 Mboe of oil and gas. The Downstream segment involves in refining, marketing, trading, and shipping crude oil and petroleum products. It also produces a range of specialty products, s uch as lubricants, LPG, jet fuel, special fluids, bitumen, marine fuels, and petrochemical feedstock. This segment holds interests in 24 refineries located in Europe, the United States, the French West Indies, Africa, and China, as well as operates a network of 17,490 service stations. The Chemicals segment produces base chemicals, including petrochemicals and fertilizers, as well as engages in rubber processing, resins, adhesives, and electroplating activities. TOTAL S.A. was founded in 1924 and is based in Paris, France.

Advisors' Opinion:

• [By Arjun Sreekumar]

  For instance, embattled British oil giant BP (NYSE: BP  ) saw its first-quarter total oil and gas production fall 5% from year-ago levels, while French oil major Total (NYSE: TOT  ) reported a 2% drop. Even Exxon, despite its massive reserves and unparalleled efficiency in allocating capital, saw a 3.5% year-over-year decline in first-quarter production.

• [By Travis Hoium]

  ABB (NYSE: ABB  ) is spending $1 billion to buy Power-One (NASDAQ: PWER.DL  ) , a major player in solar inverters. This is the latest move by a large energy company to buy into solar following Total (NYSE: TOT  ) and General Electric (NYSE: GE  ) . Will we see more solar buyouts? Erin Miller sat down with Fool contributor Travis Hoium to find out.�

Hot European Stocks To Buy For 2015: Flamel Technologies S.A.(FLML)

Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer based technology in the United Kingdom, Ireland, the United States, France, and Europe. The company develops nanogel Medusa technology, which is intended to provide controlled release following injection of therapeutic proteins, peptides, and other molecules; a microparticle adaptation of the Medusa platform that is intended for use in the delivery of smaller proteins and peptides; and Micropump technology, a microparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology, an adaptation based on Micropump technology, which is intended to minimize the misuse and abuse of medications subject to abuse. Its principal product based on Micropump technology is Coreg CR, which is intended for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. The company?s products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus and as a immune response; and FT-105, an injectable insulin formulation for diabetic patients. Its products based on its Micropump technology comprise LiquiTime for the elderly and pediatric patient patients, or others who have difficulty swallowing. The company has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; and Pfizer Inc, as well as has a joint development agreement with Digna Biotech, S.L. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France.

Hot European Stocks To Buy For 2015: STMicroelectronics N.V.(STM)

STMicroelectronics N.V., an independent semiconductor company, engages in the design, development, manufacture, and marketing of a range of semiconductor integrated circuits and discrete devices. Its products include discrete and standard commodity components, application-specific integrated circuits, custom devices and semi-custom devices, and application-specific standard products for analog, digital, and mixed-signal applications. The company also offers subsystems and modules for the telecommunications, automotive, and industrial markets comprising mobile phone accessories, battery chargers, ISDN power supplies, and in-vehicle equipment for electronic toll payment, as well as provides Smartcard products. Its products are used in various microelectronic applications consisting of automotive products, computer peripherals, telecommunications systems, consumer products, industrial automation, and control systems. The company sells its products through distributors and ret ailers. STMicroelectronics N.V. was founded in 1987 and is headquartered in Geneva, Switzerland.

Advisors' Opinion:

• [By Tim Brugger]

  In addition to the upgraded Atom processor rollout, Intel also announced a realignment of its management structure. Now comes word the "leading semiconductor company" named in a recent press release announcing the acquisition of a STMicroelectronics (NYSE: STM  ) and Ericsson (NASDAQ: ERIC  ) mobile GPS joint venture was none other than Intel. When Krzanich said he was committed to the rapidly changing mobile computing market, he wasn't kidding; and that should be sweet music to the ears of Intel shareholders.

• [By Esekla]

  Like Universal Display, InvenSense (INVN) represents a good long-term opportunity in its own right. The price entry point is not quite as good, though it has pulled back under my more recent price target of $15, when reports of a long-awaited Apple design win were challenged. Though conversations between the two are ongoing, InvenSense management's comments indicate an unwillingness to get roped into wrecking margin for volume, like many other Apple suppliers. Consequently, I don't believe they will gain Apple as a customer until the release of an iWatch or similar device that absolutely requires InvenSense's best-in-class form factors and power usage. It's also possible that continued good news on their legal battles with ST Micro (STM) could move the stock.

• [By Seth Jayson]

  STMicroelectronics (NYSE: STM  ) reported earnings on July 22. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended June 29 (Q2), STMicroelectronics met expectations on revenues and missed expectations on earnings per share.

Hot European Stocks To Buy For 2015: Aegon NV(AEG)

AEGON N.V. provides life insurance, pensions, and asset management products and services worldwide. The company?s life insurance products include traditional, term, universal, whole, and other life insurance products sold as part of defined benefit pension plans, endowment policies, post-retirement annuity products, and group risk products; supplemental health insurance products comprise accidental death, other injury, critical illness, hospital indemnity, medicare supplement, and student health; specialty lines consists of travel, membership, and creditor products; and long term care insurance products for policyholders who require care due to a chronic illness or cognitive impairment. It also offers a range of savings and retirement products and services, including mutual funds, and fixed and variable annuities, savings accounts and investment contracts, segregated funds, guaranteed investment accounts, and single premium immediate annuities, as well as investment advice to individuals. In addition, the company offers employer solutions and pensions, such as retirement plans, pension plans, and pension-related products and services; investment products, including onshore and offshore bonds, and trusts; reinsurance products and solutions to life insurance and financial services companies; general insurance products comprising house, car, and fire insurance; and asset management products and services, including general account assets, unit-linked funds, and third party activities. AEGON N.V. markets its products through independent and career agents, financial planners, registered representatives, independent marketing organizations, banks, broker-dealers, benefit consulting firms, wirehouses, affinity groups, institutional partners, independent managing general agencies, and specialized financial advisors, as well as through online, direct, and worksite marketing. The company was founded in 1900 and is headquartered in The Hague, the Netherl ands.

Hot European Stocks To Buy For 2015: British American Tobacco Industries p.l.c.(BTI)

British American Tobacco p.l.c., through its subsidiaries, engages in the manufacture, distribution, and sale of tobacco products. The company offers cigars, cigarettes, smokeless snus, roll-your-own, and pipe tobacco products under the Dunhill, Kent, Lucky Strike, Pall Mall, Vogue, Viceroy, Kool, Rothmans, Peter Stuyvesant, Benson & Hedges, and State Express 555 brand names. It has operations in the Asia-Pacific, the Americas, eastern and western Europe, Africa, and the Middle East. The company was founded in 1902 and is headquartered in London, the United Kingdom. British American Tobacco p.l.c. operates independently of Remgro Ltd. as of November 03, 2008.

Advisors' Opinion:

• [By Jon Wallis]

  LONDON -- British American Tobacco� (LSE: BATS  ) (NYSE: BTI) -- the world's second-biggest cigarette maker -- is currently up more than 2% following this morning's interim management statement for the first quarter of 2013, in which the company reported revenue growth of 5% (on a constant current basis) despite difficult market conditions.

• [By Mark Rogers]

  Today I'm looking at the earnings per share (EPS) forecasts for�British American Tobacco� (LSE: BATS  ) (NYSEMKT: BTI  ) , the FTSE 100 cigarette-manufacturing colossus. All my figures are courtesy of S&P Capital IQ.

• [By Roland Head]

  LONDON -- Tobacco giants�British American Tobacco� (LSE: BATS  ) (NYSEMKT: BTI  ) and�Imperial Tobacco Group� (LSE: IMT  ) (NASDAQOTH: ITYBY  ) sell more than 1 trillion cigarettes every year.

• [By Victor Selva]

  Investors can have another option of investing in the tobacco sector with British American Tobacco PLC (BTI). Also selling tobacco products in 180 countries, the company holds leadership positions in around 50 of them. Brands like Dunhill, Kent, Pall Mall and Lucky Strike are well known and have been gaining share over the past several years.

Hot European Stocks To Buy For 2015: Nuveen Select Tax Free Income Portfolio(NXP)

Nuveen Select Tax-Free Income Portfolio is an exchange traded fund launched by Nuveen Investments, Inc. It is managed by Nuveen Asset Management Inc. The fund invests in the fixed income markets of the United States. It primarily invests in long-term municipal obligations with investment-grade ratings (Baa and BBB or better). Nuveen Select Tax-Free Income Portfolio was formed on March 19, 1992 and is domiciled in United States.

Market Vectors Rolls Out Factor-Based ETFs

Market Vectors ETF Trust said early Thursday that it launched four new exchange-traded funds (ETFs) powered by factors, or investment screens, that track companies according to their return on equity, leverage, earnings growth and dividends.

The new ETFs are the Market Vectors MSCI International Quality ETF (QXUS), Market Vectors MSCI Emerging Markets Quality ETF (QEM), Market Vectors MSCI International Quality Dividend ETF (QDXU), and Market Vectors MSCI Emerging Markets Quality Dividend ETF (QDEM).

“Quality matters. Quality as an investment factor has historically outperformed broad international and emerging markets equities with relatively lower volatility over long time periods, but until now, a quality — focused, factor — based approach has usually been accessible only through active strategies,” said Amrita Bagaria, international-equity ETF product manager with Market Vectors, in a press release.

“We have heard the concerns of investors who understand that you need to be selective and find a way to identify quality stocks, because you don’t necessarily want to hold every single company when investing in international or emerging markets,” Bagaria explained.

QXUS’s gross expense ratio is 0.69%, and its net expense ratio is 0.45%. QEM has a gross expense ratio of 0.74% and a net expense ratio of 0.50%. QDXU’s gross expense ratio is 0.67% and its net expense ratio is 0.45%. QDEM has a gross expense ratio of 0.73% and a net expense ratio of 0.50%.

The net expense ratios for all four funds are capped contractually until at least Feb. 1, 2015, according to Market Vectors.

“Holdings in both indexes are screened for historically high return on equity [ROE], stable annual earnings growth and low financial leverage,” said Diana Tidd, managing director and head of the MSCI Index Business in the Americas, in a statement. “Our research suggests that the Quality growth companies have high ROE, low financial leverage and stable earnings that are uncorrelated with the broad business cycle and may provide diversification benefits in portfolio allocation.”

Forces Behind Factoring

iShares recencenty introduced factor-based ETFs. The iShares MSCI USA Quality Factor ETF (QUAL), for instance, now has about $290 million in assets. According to Morningstar, QUAL had a price return of 11.7% in the fourth quarter vs. 10.5% for the S&P 500.

In a 2013 report on factor-based investment, two experts at State Street Global Advisors explained that issues like market instability, lowered return expectations and higher return requirements have put traditional portfolio construction approaches under “intense scrutiny.”

“Factor-based frameworks that hold the promise of working better during periods of instability and crisis, have begun to gain traction,” wrote Stacy Marino and Rick Thomas of SSGA. “The main advantages of a factor-based approach are a better quantification of underlying risk exposures and an ability to directly benefit from factor payoffs. Its main limitation is the same limitation found in a more traditional approach.”

In other words, factor-based portfolios rely on the traditional asset classes and hence the returns they produce, they note. But such an approach may lead to well-thought-out asset allocation, “one that better aligns an investment plan’s objectives and risk tolerances with reasonable asset class exposures.”

Overall, the SSGA experts conclude, using a factor-based approach “forces an investment committee to think about the true sources of risk and return, and it opens a framework to harvest return premiums from unconventional sources.”

The current level of assets held by investors across the Market Vectors ETF product line is $22.1 billion. The product sponsor is Van Eck Global.

“By combining the search for dividend yield in international and emerging markets with MSCI’s quality screens, investors will be able to add exposures that may potentially generate excess returns and benefit their portfolios in down markets,” Bagaria said.

---

Check out Cut Out Wolves of Wall Street With These Dirt-Cheap ETFs on ThinkAdvisor.

"Insidious Chapter 2" Had Better Thank Netflix

Some sequels are better off left unmade. 

Yes, I'm talking to you, Grown Ups 2. Don't think you're getting a free pass, Speed 2: Cruise Control. If the original entry was critically panned -- cough, cough, Grown Ups -- there's no reason to keep going. If a movie works under the outrageous premise that a bus will blow up if it slows down, there's no need to whisk Sandra Bullock onto a cruise ship for a sequel to Speed.

This brings us to Insidious Chapter 2. The followup to 2011's Insidious hits a multiplex near you next weekend, and it certainly wasn't the kind of box-office smash that would send studios scrambling for a sequel. The supernatural horror flick about a family coping with a demon-possessed son took in just a little more than $54 million in its domestic theatrical run. 

However, the movie has been well reviewed. Netflix (NASDAQ: NFLX  ) users have bestowed it a rating of 3.7 stars out of five, and that's a pretty good rating on the leading video service. The movie was available for streaming on Netflix until this past May, when a licensing deal ran out, and its success there probably played a major part in the decision to for FilmDistrict to go ahead with a sequel. 

Nearly 1.8 million Netflix subscribers have rated the movie. That's huge for a movie that was seen by fewer than 7 million moviegoers when it was playing on the big screen (dividing $54 million in box office receipts by the average ticket price in 2011 of $7.93). We've seen Netflix build an audience for TV shows including Mad Men and, more recently, Breaking Bad. But now we have a good example of Netflix streaming as an asset to a theatrical franchise if the sequel manages to beat out the original. 

Source: FilmDistrict.

Top Canadian Stocks To Own For 2014

It also helps that supernatural movies have been storming back to life this year. Time Warner's (NYSE: TWX  ) The Conjuring has raked in more than $134 million in ticket sales this summer. That's not too shabby for a movie with a $20 million production budget. Mama's $71 million take earlier this year wasn't as impressive, but it still fared better than Insidious.

Let's hope that the producers of Insidious Chapter 2 keep this all in mind as the next few weeks play out. Thanking Netflix -- and The Conjuring -- won't happen. The Netflix licensing deal went away four months ago. Time Warner's creepy movie is the competition. However, it would be the right thing to do.

"It will take what you love most," is the film's tag line, but it's those two factors that helped bring it back.

If you want to see something really scary, check out the price of oil these days
Think the days of $100 oil are gone? Think again. In fact, the market is there right now. But for investors who are positioned to profit from the return of $100 oil, it can't come soon enough. To help investors get rich off rising oil prices, our top analysts prepared a free report that reveals three stocks that are bound to soar as oil prices climb higher. To discover the identities of these stocks instantly, access your free report by clicking here now.

Top 10 Stocks To Watch For 2014

Spencer Platt/Getty Images Bank of America said Thursday that it was cutting 1,200 to 1,300 mortgage jobs because of declines in refinancing activity and an improvement in its portfolio of delinquent home loans. The employees are based in divisions that handle processing new mortgages and service home loans that are past due, a spokesman said. They received notice this week that their positions were being eliminated. News of the layoffs was first reported by the Wall Street Journal. The newspaper also said Bank of America (BAC) was looking to cut 3,000 mortgage jobs by the end of the year. The spokesman couldn't immediately confirm that number. The second-largest U.S. bank laid off more than 9,000 full-time employees in the third quarter. Finance chief Bruce Thompson said on an Oct. 16 conference call with analysts that the reductions were concentrated in the unit that collects payments on current and delinquent home loans, the unit that makes new home loans, and in many of the bank's branches. Bank of America made $22.6 billion in home loans in the third quarter, down 11 percent from the second quarter. The number of mortgage applications the bank had received but not yet processed fell 60 percent from the end of June to the end of September. Also, mortgage loans that were delinquent by more than 60 days fell by 94,000 to 398,000 in the third quarter. The bank expects a further decline to below 375,000 by the end of 2013. Rising interest rates have curtailed mortgage refinancing since the spring. The interest rate on a 30-year mortgage stood at 4.39 percent in the week that ended Friday, according to the Mortgage Bankers Association, down from a high of 4.80 percent in September but above the 3.59 percent rate in early May. Bank of America expects to make fewer home loans in the fourth quarter and will look to cut more mortgage jobs, Chief Executive Officer Brian Moynihan said on the conference call. The Charlotte, N.C.-based bank isn't the only lender to lay off staff in response to a slowdown in refinancing. Wells Fargo (WFC), the largest U.S. mortgage lender, said on Oct. 17 that it was cutting 925 mortgage jobs. That comes on top of the 5,300 Wells Fargo mortgage employees that were notified that they would be laid off in the third quarter.

Top 10 Stocks To Watch For 2014: Heritage Oil Corp Com Stk Npv (HOC.TO)

Heritage Oil Plc operates as an independent oil and gas exploration and production company. It has an exploration appraisal and development asset in the Kurdistan Region of Iraq; exploration assets in Malta, Tanzania, Pakistan, Libya, and the Democratic Republic of Congo; and a producing property in Russia. The company was founded in 1992 and is headquartered in St Helier, the Channel Islands.

Top 10 Stocks To Watch For 2014: Forsys Metals Corp Com Npv(FSY.TO)

Forsys Metals Corp., an exploration stage company, together with its subsidiaries, engages in the acquisition, exploration, and development of mineral properties in Namibia. The company primarily explores for uranium and gold ores. Its flagship project is the Valencia Uranium project that covers an area of approximately 735.6 hectares located south-west of the town of Usakos in central-west Namibia. The company was formerly known as Forsys Technologies Inc. and changed its name to Forsys Metals Corp. in June 2005. Forsys Metals Corp. was incorporated in 1985 and is headquartered in Toronto, Canada.

Top Warren Buffett Companies To Invest In 2014: Nanosphere Inc.(NSPH)

Nanosphere, Inc. develops, manufactures, and markets molecular diagnostics platform, the Verigene System that enables genomic and protein testing on a single platform. Its Verigene System includes a bench-top molecular diagnostics workstation with nanoparticle technology that provides the ability to run multiple tests simultaneously on the same sample. The Verigene System is used for testing infectious disease assays, human and pharmacogenetic assays, and ultra-sensitive protein assays. The company serves hospital-based laboratories and academic research institutions in the United States. Nanosphere, Inc. was founded in 1998 and is headquartered in Northbrook, Illinois.

Advisors' Opinion:

• [By Jon C. Ogg]

  Nanosphere Inc. (NASDAQ: NSPH) is not exactly a household name in molecular diagnostics, and apparently it needs better name recognition for boosting sales. Its sales were disappointing and the stock was down almost 18% at $2.40, and now we have indications down around $2.35 in Wednesday trading indications.

• [By Roberto Pedone]

  
  

  One under-$10 medical equipment player that's quickly moving within range of triggering a major breakout trade is Nanosphere (NSPH), which develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, which enables simple, low-cost and highly sensitive genomic and protein testing on a single platform. This stock has been hit hard by the bears so far in 2013, with shares off by 27%.

  If you take a look at the chart for Nanosphere, you'll notice that this stock is just starting to spike sharply higher today back above its 50-day moving average of $2 a share. This spike is quickly pushing shares of NSPH within range of triggering a major breakout trade. That breakout will trigger once NSPH manages to take out the upper-end of its recent sideways trading chart pattern.

  Traders should now look for long-biased trades in NSPH if it manages to break out above some near-term overhead resistance levels at $2.17 to $2.20 a share and then once it takes out its gap down day high from August at $2.29 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 652,718 shares. If that breakout hits soon, then NSPH will set up to re-fill some of its previous gap down zone from August that stated just above $3 a share. If that gap gets filled with volume, then NSPH could easily tag $3.50 to $4 a share.

  Traders can look to buy NSPH off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.81 to $1.77 a share. One can also buy NSPH off strength once it clears those resistance levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Stocks To Watch For 2014: Horsehead Holding Corp.(ZINC)

Horsehead Holding Corp., together with its subsidiaries, produces and sells specialty zinc and zinc-based products in North America. The company?s products include PW zinc metal, which is used to provide a protective coating to various fabricated products, including pipe and guard rails, heat exchangers, and telecommunications towers, as well as for the production of brass; and SSHG zinc metal that is used as feed for the manufacture of high-purity zinc powder and zinc alloys. It also offers zinc oxide for the production of tire and rubber products, chemicals, ceramics, plastics, paints, lubricating oils, and pharmaceuticals. In addition, the company recycles electric arc furnace dust, a hazardous waste generated by steel mini-mills. Further, it provides special zinc powders, which are used in general chemical and metallurgical applications, as well as in friction applications, such as brake linings for automobiles; battery grade zinc powders that are used in alkaline, me rcuric oxide, silver oxide, and zinc-air batteries; and copper-based powders, including brass, bronze, and nickel-silver powders, which are used in various applications comprising brazing, infiltrating, and powdered metallurgical hardware, such as lock bodies, valves, and gears. Additionally, the company offers short-line railroad service for the movement of materials. It primarily serves galvanizers and brass producers; alkaline battery industries; and manufacturers of tire and rubber products, lubricating oils, chemicals, paints, ceramics, plastics, and pharmaceuticals. The company was incorporated in 2003 and is based in Pittsburgh, Pennsylvania.

Top 10 Stocks To Watch For 2014: Latteno Food Corp (LATF)

Latteno Food Corp. (Latteno), incorporated on August 24, 1994, is engaged in acquiring, organizing, developing and upgrading companies in the international food and beverage market. Latteno is specializing in the dairy industry and coffee industry. The Company operates through its subsidiary in Brazil. On February 10, 2010 Latteno acquired Global Milk Businesses and Administration of Private Properties Ltda. (Global Milk). Global Milk holds the rights of certain intellectual property of the brand name products manufactured and sold under the brand name Teixeira. In March 2013, the Company acquired Green Cannabis Collective Inc.

Latteno is leasing an instant and roasted coffee factory located in Cruzeiro, Sao-Paulo, which was property the Company previously owned under its BDFC Brasil Alimentos Ltda (BDFC) subsidiary. In addition to the lease, the Company has maintained ownership of four brand names, Samba Cafe, Vivenda, Torino and Brazilian Best, used in the past by Latteno to sell its instant and roasted coffee across the world. The Company engaged the service companies to assist with its operations, such as Log-Frio Ltda, SigaSolutions Ltda, Microsiga Ltda and Varistao Transportes Ltda.

The Company competes with Nestle, Companhia Cacique de Cafe Soluvel, Cafe Soluvel Brasilia and Companhia lguacu de Cafe Soluvel.

Top 10 Stocks To Watch For 2014: Stewart Information Services Corporation(STC)

Stewart Information Services Corporation provides title insurance and related information services required for settlement by the real estate and mortgage industries. It operates in two segments, Title Insurance-Related Services and Real Estate Information. The Title Insurance-Related Services segment offers services that include searching for and examining documents, such as deeds, mortgages, wills, divorce decrees, court judgments, liens, paving assessments, and tax records, as well as provides titles insurance for residential and commercial properties, undeveloped acreage, farms, ranches, and water rights. This segment serves attorneys, builders, developers, home buyers and home sellers, lenders, and real estate brokers. The Real Estate Information segment offers products and services, which primarily include lender services, title technology, foreign and domestic government services, mapping, title information, Internal Revenue Code Section 1031 tax-deferred property e xchanges, pre-employment services, and online filing and transaction management. Its customers include mortgage lenders and servicers, mortgage brokers, mortgage investors, government entities, commercial and residential real estate agents, land developers, builders, title insurance agencies, and others interested in obtaining property information, as well as accountants, attorneys, investors, and employers. The company has operations primarily in the United States, Canada, the United Kingdom, central Europe, Mexico, central America, and Australia. Stewart Information Services Corporation was founded in 1893 and is based in Houston, Texas.

Advisors' Opinion:

• [By Ben Levisohn]

  Tower Group has dropped 40% to $4.43 today, and some other small insurers are also getting dinged this morning. HCI Group (HCI) has fallen 1.8% to $39.36, Stewart Information Services (STC) has declined 0.7% to $31.36 and the Navigators Group (NAVG) has ticked down 0.4% to $56.10.

• [By James Fink]

  My housing pick is Houston-based Stewart Information Services (STC), a 120-year-old real estate business founded in 1893, that is still owned and managed by the founding family.

• [By Ben Levisohn]

  Tower Group has dropped 12% to $3.88 today at 11:39 a.m., while Stewart Information Services (STC) has dipped 0.1% to $31.16, the�Navigators Group�(NAVG) has fallen 1.4% to $54.78 and HCI Group�(HCI) has gained 1% to $38.16.

Top 10 Stocks To Watch For 2014: BT Group plc (BT)

BT Group plc provides communications solutions and services worldwide. It engages in the provision of networked IT services; and local, national, and international telecommunications services for use at home, at work, and on the move. The company also offers broadband and Internet products in the United Kingdom (U.K.), as well as TV and converged fixed/mobile services. It operates in four segments: BT Global Services, BT Retail, BT Wholesale, and Openreach. The BT Global Services segment provides managed networked IT services to multinational corporations, domestic businesses, and national and local government organizations. The BT Retail segment offers broadband, telephony, and TV services, as well IT and telephony for small to medium sized businesses in the United Kingdom. It also provides video and telephone conferencing, CCTV, and alarm systems. This segment serves corporate, small and medium enterprises, consumer, and wholesale markets in the U.K., the Republic of Ire land, and Northern Ireland. The BT Wholesale segment provides voice, broadband, and data communications services, including managed services for fixed and mobile network operators, Internet service providers, and telecoms resellers in the U.K. The Openreach segment connects communications providers? customers to their local telephone exchange, giving them access to the U.K. network. The company was formerly known as Newgate Telecommunications Limited and changed its name to BT Group plc in September 2001. BT Group plc was founded in 1981 and is based in London, the United Kingdom.

Advisors' Opinion:

• [By G. A. Chester]

  LONDON -- There are things to love and loathe about most companies. Today, I'm going to tell you about three things to love about�BT Group� (LSE: BT-A  ) (NYSE: BT  ) .

• [By Alex Jordon]

  A variety of acquisitions ramps up Oracle's presence in cloud computing, like deals with RightNow, Taleo, and Eloqua. The annual run-rate of their cloud business is already over $1 billion, larger than Workday (WDAY) and SAP (SAP) combined. New customers include British Telecom (BT), BMC Software (BMC), Siemens (SI), Yahoo (YHOO), and Intuit (INTU).

Top 10 Stocks To Watch For 2014: SeaChange International Inc.(SEAC)

SeaChange International, Inc. provides multi-screen video products and services that facilitate the aggregation, licensing, management, and distribution of video, television programming, and advertising content to cable system operators, telecommunications companies, broadcast television companies, and mobile communications providers worldwide. The company operates in two segments, Software and Media Services. The Software segment offers back-office products, including SeaChange Axiom, an on-demand back office software that allow operators to centralize video distribution systems, as well as video streamers; advertising product solutions, such as video-on-demand, digital video recorders, and over-the-top services; and home gateway product solutions, which include Nucleus, a hybrid gateway software product that provides control over channel changes, VOD/DVR playback, and trick mode set-top box functionalities. This segment also provides professional services, installation, training, project management, product maintenance, technical support, and software development related services. The Media Services segment offers content for video-on-demand and pay-per-view platforms; and marketing, promotional, and production services to cable operators and telecommunications providers. This segment also sources, acquires, packages, and markets video-on-demand services by providing access to content from local and Hollywood studio providers in various formats, including music videos, television programs, and feature length movies. The company sells and markets its products and services through a direct sales organization, independent agents, and distributors. SeaChange International, Inc. was founded in 1993 and is headquartered in Acton, Massachusetts.

Advisors' Opinion:

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to SeaChange International (Nasdaq: SEAC  ) .

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SeaChange International (Nasdaq: SEAC  ) , whose recent revenue and earnings are plotted below.

• [By Johanna Bennett]

  SeaChange (SEAC) fell 16.5% to $12.03 after the company’s guidance for the fiscal fourth quarter fell well below analysts’ expectations.

Top 10 Stocks To Watch For 2014: Ocean Wilson Hdg(OCN.L)

Ocean Wilsons Holdings Limited, through its subsidiaries, provides maritime and logistics services in Brazil. The company offers maritime services, which include harbor and ocean towage, container terminal operation, offshore support, logistics, small vessel construction, and ship agency services. It operates port terminals, which offer assistance in port operations for loading and unloading of vessels, storage, and auxiliary services, as well as provides platform supply vessels to transport equipment and supplies to and from offshore oil and gas installations. The company also provides harbor and ocean towage, salvage support, and maritime support to the offshore oil and gas industry, as well as various logistics services, such as storage, customs storage, distribution, highway transportation, multimodal transportation, and non vessel operating common carrier services. In addition, it operates a ship agency that provides commercial representation, cargo documentation, con tainer control, and vessel support services for ship owners; and holds a portfolio of international investments. The company has operations in Bermuda, Brazil, and the United Kingdom. Ocean Wilsons Holdings Limited is based in Hamilton, Bermuda.

Top 10 Stocks To Watch For 2014: Tucows Inc Com Npv (TC.TO)

Tucows Inc. distributes Internet services worldwide. The company offers domain name registration, and security and identity products through digital certificates, email, and mobile telephony services. It provides OpenSRS, a wholesale service, which manages domain names, mailboxes, and digital certificates through a network of approximately 11,000 Web hosts, Internet service providers (ISPs), and other resellers; Platypus, a billing service that provides ISPs with an industry-specific solution for billing, service provisioning, and customer account management; and Hover, a retail service, which offers domain names, mailboxes, and digital certificates management services for consumers and small businesses. In addition, the company offers YummyNames that manages various domain names with a portfolio of approximately 42,000 domains; and Butterscotch, a content service, which operates butterscotch.com and tucows.com advertising-supported Websites that provide content in the for m of approximately 4,000 videos and 385,000 software and mobile listings, and articles. The company was formerly known as Infonautics, Inc. and changed its name to Tucows Inc. in August 2001. Tucows Inc. was founded in 1992 and is headquartered in Toronto, Canada.

Study: Gen Y may like cars after all

New findings from consulting giant Deloitte debunk a notion held in recent years that young people don't want to drive anymore.

Generation Y — born roughly from 1977 to 1994 — are more than 80 million strong and nearly 50 million of them plan to buy a new or used car in the next three years, according to Craig Griffi, Deloitte vice chairman and automotive practice leader

"There's been a lot of conjecture about whether Gen-Yers even like driving," Griffi said. But Deloitte found nearly two-thirds of Gen Y Americans "would indicate that they love their cars."

Nearly 700 Gen-Y-age Americans participated in Deloitte's survey, which encompassed more than 23,000 respondents across 19 countries. The company will release full results later this year, but it disclosed some findings earlier this week on a group that automakers have spent years trying to understand.

To be sure, Deloitte notes some of America's car culture has been lost. Gen Y faces three barriers to vehicle shopping: needs being met by other transportation like walking, mass transit and car-sharing programs; operational costs such as fuel and maintenance; and vehicle affordability.

Start with the first one. More than two-thirds of Gen Y consumers "would prefer to live in neighborhoods with everything in walking distance," Griffi said. Given rising traffic congestion, that isn't necessarily a problem, but "obviously the vehicle starts to become less important," he added.

Unless it drives itself. A high percentage Gen Y consumers view self- driving cars — anathema to performance enthusiasts, but an inexorable goal for the auto industry — as a big benefit, said Joe Vitale, who leads Deloitte's global automotive sector.

That doesn't mean Gen Y wants to abandon wheels altogether. Just 29 percent said they'd be willing to give up their personal cars for other forms of mobility, Deloitte notes. Semi-autonomous technologies that help drivers avoid accidents score big with the group. Some four-fifths of resp! ondents rated technology that helps the vehicle avoid crashes as very important, Vitale said.

Hot Canadian Companies To Buy For 2014

Kabe Exploration Inc. (KABX)

Today, KABX has shed (-5.26%) down -0.0010 at $.0180 with�158,078 shares in movement thus far (ref. google finance Delayed: 12:22PM EDT June 19, 2013), but don�� let this get you down.

Kabe Exploration Inc. previously reported it has entered into a letter of intent to form a joint venture partnership with Canadian oil and gas holding company International Equity Partners Oil & Gas, Inc. for the exploration and development of 7,300 acres of oil leases in the highly productive Mississippian field of southern Kansas. International Equity Partners Oil & Gas will contribute capital and expertise toward developing the assets for production. KABE�� five year operational plan is expected to bring 24 new oil wells into production.

Take a look at Kabe Exploration Inc. (KABX) 5 day chart:

Hot Canadian Companies To Buy For 2014: Brookfield Office Properties Inc. (BPO)

Brookfield Properties Corporation is a publicly owned real estate investment firm. The firm engages in the ownership, development, and management of premier commercial properties. It also provides ancillary real estate service businesses, such as tenant service and amenities. The firm invests in the real estate markets of the United States with a focus on North American cities, including New York, Boston, Washington, D.C., Toronto, Calgary, Denver, and Minneapolis. It primarily invests in properties and development sites predominantly office buildings. The firm operates as a subsidiary of Brookfield Asset Management Inc. It was formerly known as Carena-Bancorp Holdings, Inc. and changed its name to Le Holding Carena-Bancorp Inc. in 1978. The company further changed its name to Carena-Bancorp, Inc. in 1985; to Carena Developments Limited in 1989; and to Brookfield Properties Corporation in 1996. Brookfield Properties was founded in 1923 and is based in New York, New York wi th an additional office in Toronto, Canada

Advisors' Opinion:

• [By Luke Jacobi]

  Brookfield Office Properties (NYSE: BPO) got a boost, closing up 13.71 percent to $19.07 after Brookfield Property Partners (NYSE: BPY) proposed to acquire Brookfield Office Properties for $19.34 per share.

• [By Jake L'Ecuyer]

  Shares of Brookfield Office Properties (NYSE: BPO) got a boost, shooting up 13.45 percent to $19.02 after Brookfield Property Partners (NYSE: BPY) proposed to acquire Brookfield Office Properties for $19.34 per share.

Hot Canadian Companies To Buy For 2014: Potomac Electric Power Company(POM)

Pepco Holdings, Inc., through its subsidiaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. It distributes electricity to approximately 1.8 million customers in the mid-Atlantic region and delivers natural gas to approximately 123,000 customers in Delaware. In addition, the company involves in the retail supply of electricity and natural gas; provision of energy efficiency services to federal, state, and local government customers; and designs, constructs, and operates combined heat and power and central energy plants, as well as owns and operates two oil-fired generation facilities. Further, it offers high voltage electric construction and maintenance services, low voltage electric construction and maintenance services, and streetlight construction and asset management services to utilities, municipalities, and other customers in the Washington, District of Columbia. Additionally, the company holds investments in eight cross-border energy leases. Pepco Holdings, Inc. was founded in 1896 and is based in Washington, District of Columbia.

Advisors' Opinion:

• [By Sally Jones]

  
  Highlight: Pepco Holdings Inc. (POM)

  The POM share price is currently $18.17 or 20.0% off the 52-week high of $22.72. Its yield is 5.90%.

Top 5 Oil Companies To Own In Right Now: DCP Midstream Partners LP (DPM)

DCP Midstream Partners, LP, together with its subsidiaries, engages in gathering, compressing, treating, processing, transporting, storing, and selling natural gas in the United States. It also transports, stores, and sells propane in wholesale markets; and produces, fractionates, transports, stores, and sells natural gas liquids (NGLs) and condensate. The company operates in three segments: Natural Gas Services, Wholesale Propane Logistics, and NGL Logistics. The Natural Gas Services segment operates Northern Louisiana system that gathers, process, and transports natural gas; Southern Oklahoma system; Colorado system; Wyoming system that covers 1,300 miles of natural gas gathering pipelines that cover approximately 4,000 square miles in the Powder River Basin in Wyoming; and Michigan system. It also operates Discovery system, East Texas system, and Southeast Texas system. The Wholesale Propane Logistics segment owns and operates a propane marine import terminal; a leased propane marine terminal; a propane pipeline terminal; and six propane rail terminals, as well as access to several open access pipeline terminals. This segment sells its propane to retail propane distributors. The NGL Logistics segment operates Seabreeze and Wilbreeze NGL transportation pipelines, the Wattenberg NGL transportation pipeline, the Black Lake interstate NGL pipeline, and the NGL storage facility in Marysville, Michigan. DCP Midstream Partners, LP was founded in 2005 and is based in Denver, Colorado.

Hot Canadian Companies To Buy For 2014: Assisted Living Concepts Inc. New (ALC)

Assisted Living Concepts, Inc., together with its subsidiaries, operates senior living residences in the United States. It offers general services, such as meals, activities, laundry, and housekeeping; support services, including assistance with medication, monitoring health status, co-ordination of transportation, and co-ordination with physician offices; and personal care services, such as dressing, grooming, and bathing. The company also arranges access to additional services from third-party providers, including physical, occupational, and respiratory therapy; home health; hospice; and pharmacy services. As of December 31, 2011, it operated 211 senior living residences comprising 9,325 units in 20 states. Assisted Living Concepts, Inc. was founded in 1994 and is headquartered in Menomonee Falls, Wisconsin.

Hot Canadian Companies To Buy For 2014: Penn West Petroleum Ltd(PWE)

Penn West Petroleum Ltd. engages in acquiring, exploring, developing, exploiting, and holding interests in petroleum and natural gas properties and related assets in North America. The company produces light and medium crude oil, natural gas liquids, heavy oil, and natural gas. It operates in two major regions, including the Southern District, which covers properties within Manitoba, Saskatchewan, and southern and east central Alberta with developed and undeveloped land base totaling approximately 3.3 million net acres; and the Northern District encompassing northeastern British Columbia, northern Alberta, parts of west central Alberta, and the Northwest Territories with developed and undeveloped land position of approximately 2.9 million net acres. The company was formerly known as Penn West Energy Trust and changed its name to Penn West Petroleum Ltd. in January 2011. Penn West Petroleum Ltd. was founded in 1979 and is headquartered in Calgary, Canada.

Advisors' Opinion:

• [By Stephan Dube]

  Peace River's most notable producers:

  PennWest Exploration (PWE), see article here.Royal Dutch Shell (RDS.A), see article here.Baytex (BTE), see article here.Strata Oil and Gas (SOIGF.PK), see article here.Petrobank Energy & Resources (PBEGF.PK), see article here.

  Cold Lake's most notable producers:

• [By Dan Caplinger]

  The biggest worry that some investors have about Pengrowth is that its dividend is large compared to its earnings. Similar issues forced Penn West Petroleum (NYSE: PWE  ) , also a former Canroy, to cut its dividend a couple months ago. Although extraordinary measures have helped Pengrowth and Enerplus (NYSE: ERF  ) sustain payouts at levels that were last reduced in the middle of 2012, both companies could eventually see further pressure on their payouts in future.

• [By Alex Planes]

  One thing investors need to watch is Pengrowth's sky-high payout ratio, which, at present levels, is clearly unsustainable. Pengrowth's asset sales will help paper over the shortfall in the near term, but it's not good policy to pay out so much in the middle of a major exploration project. The company has no plans to cut its dividend, in spite of anticipated production declines in the near term, which stands in stark contrast to competitor Penn West (NYSE: PWE  ) , which slashed its dividend by nearly half�in a wide-ranging announcement earlier this week. Both Pengrowth and Penn West trade at substantial discounts to book value, but at least Pengrowth's monster dividend gives investors something more substantial while waiting for big exploration projects to bear fruit. However, given the company's multi-year weakness, it will take a strong stomach, and a very firm belief in Pengrowth's prospects, to jump in today.

• [By Eric Volkman]

  Penn West (NYSE: PWE  ) is about to change the nameplate on its CEO's office. The company announced that current Chief Executive and President Murray Nunns has announced his departure, effective July 1. Starting June 19, his place will be taken by David Roberts, onetime executive vice president and chief operating officer of Marathon Oil. Penn West said it intends to name him to its board of directors once he takes up the CEO post.

Hot Canadian Companies To Buy For 2014: Ingram Micro Inc. (IM)

Ingram Micro Inc. distributes information technology (IT) products; and provides supply chain solutions, mobile device lifecycle services, and logistics solutions worldwide. The company�s IT peripherals include printers, scanners, displays, projectors, monitors, panels, mass storage, and tape; large format LCD and plasma displays, enclosures, mounts, media players, content software, and content creation and hosting; mobile phones, digital cameras and video disc players, game consoles, televisions, audio, media management, and home control products; barcode/card printers, AIDC scanners and software, and wireless infrastructure products; IP video surveillance, security and fire alarm systems, and access control smart cards; processors, motherboards, hard drives, and memory products; and ink and toner supplies, paper, carrying cases, and anti-glare screens. It also provides various systems, including rack, tower, and blade servers; desktops; portable personal computers and t ablets; and software products, such as business application, operating system, entertainment, security, storage, and virtualization software products, as well as middleware and developer software tools. The company�s networking products comprise switches, hubs, routers, wireless local area networks, wireless wide area networks, network interface cards, cellular data cards, network-attached storage, and storage area networks; voice over Internet protocol, communications, modems, phone systems, and video/audio conferencing; and firewalls, virtual private networks, intrusion detection, and authentication devices and appliances. In addition, it provides integration, technical support, training, financial and credit, marketing, predictive analytics, eCommerce, reseller community hosting, managed, cloud, managed print, and professional services. The company sells its products to resellers through sales representatives. Ingram Micro Inc. was founded in 1979 and is headquartered in Santa Ana, California.

Advisors' Opinion:

• [By Jon C. Ogg]

  The first list of 24/7 Wall St. stocks under book value for the month of August are Apache Corp. (NYSE: APA), Fresh Del Monte Produce Inc. (NYSE: FDP), Genworth Financial Inc. (NYSE: GNW), Ingram Micro Inc. (NYSE: IM) and JetBlue Airways Corp. (NASDAQ: JBLU). We generally have�focused on net asset values and tangible book values, as well as forward price-to-earnings multiples, share price performance, analyst expectations via the Thomson Reuters consensus price target and more.

• [By Geoff Gannon]

  A huge net-net like Ingram Micro (IM) with nine out of ten years of profits in the last decade is pretty unusual. And Ingram operates on a razor-thin margin. It usually makes about one cent in profit for every dollar of sales.

• [By Keith Speights]

  My take is that Qualcomm has rapidly established itself as the de facto standard for connecting with medical devices. The company isn't doing it alone, though. It teamed with Ingram Micro (NYSE: IM  ) , the world's largest technology distributor, to support the implementation, logistics, and financial services related to the 2net hub and platform. This partnership should help propagate Qualcomm's technology more effectively than the company could have done on its own.

Hot Canadian Companies To Buy For 2014: KBR Inc. (KBR)

KBR, Inc. operates as an engineering, construction, and services company supporting the energy, hydrocarbon, government services, minerals, civil infrastructure, power, and industrial sectors worldwide. Its Downstream business unit provides front end engineering design; detailed engineering; engineering, procurement, and construction (EPC); EPC management; and program management services to petrochemical, refining, coal gasification, and syngas markets. The company?s Government and Infrastructure business unit provides program and project management, contingency logistics, operations and maintenance, construction management, engineering, and other services to military and civilian branches of governments and private clients. Its Services business unit delivers engineering, construction, construction management, fabrication, maintenance, and turnaround services. It also offers maintenance, construction, and drilling support services for offshore oil and gas producing facili ties using semisubmersible vessels. This segment serves oil, gas, petrochemicals, and hydrocarbon processing industries, as well as power, alternate energy, pulp and paper, industrial and manufacturing, and pharmaceutical industries. The company?s Technology business unit offers various process technologies, including value-added technologies in the coal monetization, petrochemical, refining, and syngas markets. Its Upstream business unit constructs liquefied natural gas, gas-to-liquids, onshore oil and gas production facilities, offshore oil and gas production facilities, and onshore and offshore pipelines. The company?s Ventures business unit invests in and manages projects, where the company provides engineering, construction, construction management or operations, and maintenance services. KBR, Inc. was founded in 1901 and is based in Houston, Texas.

Advisors' Opinion:

• [By Monica Gerson]

  KBR (NYSE: KBR) is expected to post its Q3 earnings at $0.70 per share on revenue of $1.99 billion.

  Zynga (NASDAQ: ZNGA) is estimated to post a Q3 loss at $0.04 per share on revenue of $142.67 million.

Hot Canadian Companies To Buy For 2014: Canadian National Railway Company(CNI)

Canadian National Railway Company, together with its subsidiaries, engages in the rail and related transportation business in North America. It provides transportation for various goods, including petroleum and chemicals, grain and fertilizers, coal, metals and minerals, forest products, and intermodal and automotive products. The company operates a network of approximately 20,600 route miles of track that spans Canada and mid-America, from the Atlantic and Pacific oceans to the Gulf of Mexico. It serves the ports of Vancouver, Prince Rupert (British Columbia), Montreal, Halifax, New Orleans, and Mobile (Alabama), as well as metropolitan areas of Toronto, Buffalo, Chicago, Detroit, Duluth (Minnesota)/Superior (Wisconsin), Green Bay (Wisconsin), Minneapolis/St. Paul, Memphis, and Jackson (Mississippi), with connections to various points in North America. The company was founded in 1922 and is headquartered in Montreal, Canada.

Advisors' Opinion:

• [By Rich Smith]

  On Wednesday, Westport announced it has begun producing liquefied natural gas (LNG) "tenders" for use by Canadian National Railway (NYSE: CNI  ) . A tender�is a train car whose primary purpose is carrying fuel to supply the train's locomotive engine. Westport plans to deliver its first such tender to CNR in Q4 of this year, with three more tenders to follow subsequently.

• [By Neil Macneale]

  Both Canadian National Railway (CNI) and VF Corporation (VFC) show very similar numbers in many of the critical categories in our screening process.

• [By Isac Simon]

  An appropriate reaction?
  The market's reaction to railroad companies hasn't been favorable. Canadian National Railway (NYSE: CNI  ) (NYSE: CNI  ) traded down today by 0.6%, while Union Pacific (NYSE: UNP  ) (NYSE: UNP  ) lost more than 0.7% of its market value. Clearly, the markets took Saturday's accident seriously. However, with so much crude oil ready for cross-country trips, railroad companies are unlikely to be affected in the grander scheme of things, at least in the near term.

Best Biotech Companies To Own In Right Now

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sunesis Pharmaceuticals (NASDAQ: SNSS  ) has received an alarming one-star ranking.

With that in mind, let's take a closer look at Sunesis and see what CAPS investors are saying about the stock right now.

Sunesis facts

Headquarters (founded)

South San Francisco, Calif. (1998)

Market Cap

$280.8 million

Industry

Biotechnology

Trailing-12-Month Revenue

$5.7 million

Best Biotech Companies To Own In Right Now: InterMune Inc.(ITMN)

InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It markets pirfenidone, an orally active drug that inhibits the synthesis of TGF-beta under the Esbriet name in the European Union, as well as in a Phase III clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the Pirespa trade name. The company?s research programs focus on the discovery of small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Advisors' Opinion:

• [By Sean Williams]

  InterMune (NASDAQ: ITMN  )
  InterMune shares may have exploded higher by 30% over the past week, but there's certain to be a lot of nail-biting on the part of shareholders as we head into earnings season. The reason has been the slow acceptance of the company's idiopathic pulmonary fibrosis drug, Esbriet, based on its pricing in the EU. In previous quarters Esbriet sales have disappointed in a big way, but are expected to rise by 134% to nearly $13 million from last year, though losses are still anticipated to come in at $0.70 per share. Following its recent pop, Esbriet sales had better hit the mark, otherwise InterMune shareholders are probably going to be in for a long day.

Best Biotech Companies To Own In Right Now: Celgene Corp (CELG.O)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acq uired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufac turing facility in Boudry, Switzerland.

Comme! rc! ial Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the tre atment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its ! Syste! m ! for Tha! lidomide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed t o Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin -2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a,! leukotri! en! es, and n! itric oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosi s and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical s! tudies ha! ve been! complete! d. An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Hot Clean Energy Companies To Watch For 2014: Dyadic International Inc (DYAI)

Dyadic International, Inc. (Dyadic), incorporated in September 2002, is a holding company. The Company is a global biotechnology company. The Company has operations at the United States and the Netherlands. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of enzymes and proteins for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies, the sale of its enzymes and conducting research and development (R&D) activities for third parties. The Company operates in two segments: the United States operations and The Netherlands operations. The United States segment includes a subsidiary in Poland.

The United States operating segment is a developer, manufacturer and distributor of enzyme products, proteins, peptides and other bio-molecules derived from genes and a collaborative licensor of enabling technologies for the development and manufacturing of biological products and use in R&D. The Netherlands operating segment is also a researcher and developer of enzyme products, proteins, peptides and other bio-molecules derived from genes and, to date, has mainly invested in R&D activities.

Dyadic�� R&D activities focus on its fungal strains and associated technologies. Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. Dyadic manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuels industries.

Dyadic also utilizes a technology platform based on its patented and C1 fungus (the C1 Platform Technology), which enables the development and manufacture of proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. The C1 Platf! orm Technology also has the potential of developing and producing other biological products such as antibodies, vaccines, proteins and polypeptides for the biopharmaceutical industry.

Best Biotech Companies To Own In Right Now: Prima BioMed Ltd (PBMD.W)

Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates.

Best Biotech Companies To Own In Right Now: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Best Biotech Companies To Own In Right Now: Galectin Therapeutics Inc (GALT)

Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., incorporated on January 26, 2001, is a development-stage company. The Company is engaged in drug development to create therapies for cancer and fibrotic disease. As of December 31, 2011, the Company has two compounds in development, one is to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from different natural starting materials, both possessing the property, which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, the Company's product candidate for cancer therapy, is a linear polysaccharide polymer consisted of mannose and galactose that has a defined chemical structure and is derived from a plant source. GR-MD-02, the Company's product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source.

GM-CT-01 has in development for the therapy of colorectal cancer and is in a Phase I/II clinical trial as a combination therapy with a tumor vaccine in patients with advanced melanoma. Based on the completed Phase I and partially completed Phase II clinical trials, the Company is exploring two additional potential indicia for the use of GM-CT-01 in combination with cancer chemotherapy. There are two additional pathways for the development of GM-CT-01 for use in treatment of cancer. GM-CT-01 was found to be generally safe when studied in a Phase I clinical trial in end-stage cancer patients with multiple tumor types alone and in combination with 5-Fluorouracil (5-FU), which is an Food and Drug Administration (FDA)-approved chemotherapy used for treatment of various types of cancer.

Advisors' Opinion:

• [By Roberto Pedone]

   

  Galectin Therapeutics (GALT) offers drug research and development to create new therapies for fibrotic disease and cancer. This stock closed up 9.6% to $12.06 in Monday's trading session.

   

  Monday's Volume: 674,000
  
  Three-Month Average Volume: 222,171
  
  Volume % Change: 149%

   

  Shares of GALT jumped higher on Monday after Ascendiant initiated coverage on the stock with a buy recommendation.

   

   

  From a technical perspective, GALT spiked sharply higher here with strong upside volume. This stock has been uptrending for the last three months, with shares ripping higher from its low of $3.95 to its recent high of $13.21. During that move, shares of GALT have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GALT within range of triggering a near-term breakout trade. That trade will hit if GALT manages to take out Monday's high of $12.44 and then once it clears its 52-week high at $13.21 with high volume.

   

  Traders should now look for long-biased trades in GALT as long as it's trending above some near-term support levels at $11 or at $10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 222,171 shares. If that breakout hits soon, then GALT will set up to enter new 52-week-high territory above $13.21, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.

   

Best Biotech Companies To Own In Right Now: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Jay Silverman]

  Over the past year, including the end of this year, we've had new blockbuster drugs for hepatitis C, which is Gilead's (GILD) drug, and also for B-cell lymphomas, which is Pharmacyclics' (PCYC) drug. Those are looking to be two of the biggest drugs ever.

• [By Keith Speights]

  Pharmacyclics (NASDAQ: PCYC  ) and development partner Janssen, a division of Johnson & Johnson (NYSE: JNJ  ) , announced on Wednesday that a New Drug Application, or NDA, has been submitted for ibrutinib. The NDA filed with the U.S. Food and Drug Administration requests marketing approval for the drug in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and in the treatment of previously treated patients with mantle cell lymphoma.

Best Biotech Companies To Own In Right Now: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

Advisors' Opinion:

• [By John Udovich]

  Although its summer, there has been a steady stream of good news about medical marijuana even though important small cap marijuana stocks�Medical Marijuana Inc (OTCMKTS: MJNA) and Cannabis Science Inc (OTCMKTS: CBIS) have been fairly quietly lately while Growlife Inc (OTCBB: PHOT), a more indirect play on the spread of legalized marijuana, has produced�some news for investors:

• [By James E. Brumley]

  Wow. That didn't take long. It was only two days ago that marijuana stocks like Growlife Inc. (OTCBB:PHOT), Medical Marijuana Inc. (OTCMKTS:MJNA), Cannabis Science Inc. (OTCMKTS:CBIS), Medbox Inc. (OTCMKTS:MDBX), and Hemp, Inc. (OTCMKTS:HEMP) were all the rage, flying high on the heels of a new year... a new year in which marijuana was legalized (for one reason or another) in two more states. HEMP was up as much as 700% in less than three weeks at one point. MDBX gained 300% at the beginning of the year, when recreational marijuana began to be legally sold in Colorado. CBIS jumped 400% off of its December low. MJNA nearly doubled on the advent of new marijuana venues. PHOT soared more than 130% since the end of last year on the legalization of marijuana. It was, truthfully, some of the fastest big money that traders have ever made in the market.

• [By Bryan Murphy]

  The last few days have been nothing less than incredible for stocks like Cannabis Science Inc. (OTCMKTS:CBIS), Medbox Inc. (OTCMKTS:MDBX), Growlife Inc. (OTCBB:PHOT), and Medical Marijuana Inc. (OTCMKTS:MJNA). MJNA shares have jumped 90% since last Friday. PHOT is up 51% for the same timeframe. CBIS has grown 150%, while MDBX is up 112%. The reason? It's largely the legalization of recreational marijuana in Colorado - a law that went into effect as of January 1st. The legalization of medical marijuana in Illinois on the same day didn't hurt either. And truth be told, the event-based rally from the likes of Medbox and Cannabis Science makes basic sense - it's a landmark shift in the way this country views and treats marijuana. On the flipside, before wading any deeper into stocks like Medical Marijuana or Growlife, current and would-be owners might want to take a step back and look at the bigger picture.

• [By Bryan Murphy]

  The difference between Growlife's leadership and, say that of competitors like Cannabis Science Inc. (OTCMKTS: CBIS) or Medical Marijuana Inc. (OTCMKTS: MJNA), has been relatively well documented here at the SmallCap Network site. I think the way I - well, someone else - put it back on June 25th says it best...."Growlife is sort of the demure girl in the corner who doesn't do shots off her navel in the bar." It may not have sizzle, but it does have substance.